

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

MESALAZINE ENTERIC-COATED TABLETS OBTAIN DRUG REGISTRATION APPROVAL

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mesalazine Enteric-Coated Tablets (0.5g) (the “**Product**”) developed by the Group have obtained the drug registration approval from the National Medical Products Administration of the People’s Republic of China and are deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Mesalazine primarily exerts its therapeutic effect through modulation of the inflammatory markers associated with intestinal mucosal inflammation. It achieves anti-inflammatory effects by inhibiting the synthesis of pro-inflammatory prostaglandins and the formation of inflammatory mediator leukotrienes, demonstrating superior therapeutic efficacy in managing the inflammatory conditions in the connective tissues of the intestinal wall. The Product is indicated for the treatment of ulcerative colitis, including both the treatment of acute episodes and the maintenance of remission, as well as for the treatment of acute episodes of Crohn’s disease. The Product has a significant inhibitory effect on the inflammation of the intestinal wall and is an aminosalicylate anti-inflammatory drug widely used around the world.

The approval of the Product will further enrich the Group’s product portfolio in the therapeutic area of immune system.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 4 July 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.